Elizabeth L Salsgiver1, Aliza K Fink2, Emily A Knapp2, John J LiPuma3, Kenneth N Olivier4, Bruce C Marshall2, Lisa Saiman5. 1. Columbia University Medical Center, New York, NY. 2. Cystic Fibrosis Foundation, Bethesda, MD. 3. University of Michigan, Ann Arbor, MI. 4. National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. 5. Columbia University Medical Center, New York, NY. Electronic address: LS5@cumc.columbia.edu.
Abstract
BACKGROUND: Monitoring potential changes in the epidemiology of cystic fibrosis (CF) pathogens furthers our understanding of the potential impact of interventions. METHODS: We performed a retrospective analysis using data reported to the Cystic Fibrosis Foundation Patient Registry (CFFPR) from 2006 to 2012 to determine the annual percent changes in the prevalence and incidence of selected CF pathogens. Pathogens included Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant S aureus (MRSA), Haemophilus influenzae, Burkholderia cepacia complex, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans. Changes in nontuberculous mycobacteria (NTM) prevalence were assessed from 2010 to 2012, when the CFFPR collected NTM species. RESULTS: In 2012, the pathogens of highest prevalence and incidence were MSSA and P aeruginosa, followed by MRSA. The prevalence of A xylosoxidans and B cepacia complex were relatively low. From 2006 to 2012, the annual percent change in overall (as well as in most age strata) prevalence and incidence significantly decreased for P aeruginosa and B cepacia complex, but significantly increased for MRSA. From 2010 to 2012, the annual percent change in overall prevalence of NTM and Mycobaterium avium complex increased. CONCLUSIONS: The epidemiology of CF pathogens continues to change. The causes of these observations are most likely multifactorial and include improvements in clinical care and infection prevention and control. Data from this study will be useful to evaluate the impact of new therapies on CF microbiology.
BACKGROUND: Monitoring potential changes in the epidemiology of cystic fibrosis (CF) pathogens furthers our understanding of the potential impact of interventions. METHODS: We performed a retrospective analysis using data reported to the Cystic Fibrosis Foundation Patient Registry (CFFPR) from 2006 to 2012 to determine the annual percent changes in the prevalence and incidence of selected CF pathogens. Pathogens included Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant S aureus (MRSA), Haemophilus influenzae, Burkholderia cepacia complex, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans. Changes in nontuberculous mycobacteria (NTM) prevalence were assessed from 2010 to 2012, when the CFFPR collected NTM species. RESULTS: In 2012, the pathogens of highest prevalence and incidence were MSSA and P aeruginosa, followed by MRSA. The prevalence of A xylosoxidans and B cepacia complex were relatively low. From 2006 to 2012, the annual percent change in overall (as well as in most age strata) prevalence and incidence significantly decreased for P aeruginosa and B cepacia complex, but significantly increased for MRSA. From 2010 to 2012, the annual percent change in overall prevalence of NTM and Mycobaterium avium complex increased. CONCLUSIONS: The epidemiology of CF pathogens continues to change. The causes of these observations are most likely multifactorial and include improvements in clinical care and infection prevention and control. Data from this study will be useful to evaluate the impact of new therapies on CF microbiology.
Authors: Lisa Saiman; Jane D Siegel; John J LiPuma; Rebekah F Brown; Elizabeth A Bryson; Mary Jo Chambers; Veronica S Downer; Jill Fliege; Leslie A Hazle; Manu Jain; Bruce C Marshall; Catherine O'Malley; Suzanne R Pattee; Gail Potter-Bynoe; Siobhan Reid; Karen A Robinson; Kathryn A Sabadosa; H Joel Schmidt; Elizabeth Tullis; Jennifer Webber; David J Weber Journal: Infect Control Hosp Epidemiol Date: 2014-07-01 Impact factor: 3.254
Authors: Marianne S Muhlebach; Meredith Miller; Lisa M LaVange; Greg Mayhew; Jennifer S Goodrich; Melissa B Miller Journal: J Cyst Fibros Date: 2011-03-21 Impact factor: 5.482
Authors: Todd MacKenzie; Alex H Gifford; Kathryn A Sabadosa; Hebe B Quinton; Emily A Knapp; Christopher H Goss; Bruce C Marshall Journal: Ann Intern Med Date: 2014-08-19 Impact factor: 25.391
Authors: Anne Stone; Lynne Quittell; Juyan Zhou; Luis Alba; Meera Bhat; Joan DeCelie-Germana; Sujatha Rajan; Lynn Bonitz; John J Welter; Allen J Dozor; Ingrid Gherson; Franklin D Lowy; Lisa Saiman Journal: Pediatr Infect Dis J Date: 2009-10 Impact factor: 2.129
Authors: Cassandra E Nelson; Weiliang Huang; Luke K Brewer; Angela T Nguyen; Maureen A Kane; Angela Wilks; Amanda G Oglesby-Sherrouse Journal: J Bacteriol Date: 2019-05-22 Impact factor: 3.490
Authors: Megan Y Nas; Richard C White; Ashley L DuMont; Alberto E Lopez; Nicholas P Cianciotto Journal: Infect Immun Date: 2019-08-21 Impact factor: 3.441
Authors: Lindsay J Caverly; Theodore Spilker; Linda M Kalikin; Terri Stillwell; Carol Young; David B Huang; John J LiPuma Journal: Antimicrob Agents Chemother Date: 2019-12-20 Impact factor: 5.191
Authors: Sonya L Heltshe; Jonathan Cogen; Kathleen J Ramos; Christopher H Goss Journal: Am J Respir Crit Care Med Date: 2017-04-15 Impact factor: 21.405
Authors: Zhe Hui Hoo; Elizabeth Coates; Chin Maguire; Hannah Cantrill; Nadia Shafi; Edward F Nash; Angela McGowan; Stephen J Bourke; William G Flight; Thomas V Daniels; Julia A Nightingale; Mark I Allenby; Rachael Curley; Martin J Wildman Journal: Eur J Clin Microbiol Infect Dis Date: 2018-08-18 Impact factor: 3.267
Authors: Mila M Almeida; Meyvianne T Freitas; Tania W Folescu; Monica C Firmida; Ana Paula D'A Carvalho-Assef; Elizabeth A Marques; Robson S Leão Journal: Curr Microbiol Date: 2021-01-06 Impact factor: 2.188
Authors: S L Heltshe; U Khan; V Beckett; A Baines; J Emerson; D B Sanders; R L Gibson; W Morgan; M Rosenfeld Journal: J Cyst Fibros Date: 2017-10-28 Impact factor: 5.482